H.C. Wainwright analyst Patrick Trucchio initiated coverage of Bright Minds Biosciences (DRUG) with a Buy rating and $85 price target Bright Minds is a biotechnology company that has developed selective serotonergic agonists, providing a “rich” portfolio of new chemical entity programs in neurology and psychiatry, the analyst tells investors in a research note. The firm says the company’s lead compound BMB-101, which targets the serotonin 2C receptor, appears well positioned as a potential broad anti-seizure epilepsy medicine.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG:
- Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS Therapeutics
- Bright Minds Biosciences appoints Stephen Collins as Chief Medical Officer
- Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase
- Bright Minds Biosciences initiated with an Outperform at Baird
- Bright Minds Biosciences to Present Novel Epilepsy Data